Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised controlled trial to evaluate options for second-line therapy in patients failing a first-line 2 nucleoside reverse transcriptase inhibitors (2NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen in Africa.

Next Previous
Search
Trial Profile

A randomised controlled trial to evaluate options for second-line therapy in patients failing a first-line 2 nucleoside reverse transcriptase inhibitors (2NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen in Africa.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Abacavir; Non-nucleoside reverse transcriptase inhibitors; Raltegravir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms EARNEST; EARNEST-GSS-II

    • Most Recent Events

    • 23 Jan 2023 Results (n=208) assessing the effects of different levels of loss of viral control on immune reconstitution and activation Uganda and Zimbabwe, published in the AIDS.
    • 28 Jul 2018 Results published in the Clinical Infectious Diseases
    • 16 Nov 2015 Primary endpoint has not been met (good disease control at week 96), as per results published in the JAIDS.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top